Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...

Find insight on Fisher & Paykel Healthcare, Hims & Hers, GSK and more in the latest Market Talks covering health care.

Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Roche Holdings AG (OTC ... composite disability over a period of at least 120 weeks of treatment. Also Read: Pharmaceutical Firms Say UK Investment Is ‘Unlikely’ Unless Payment Levy Is ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Roche Holdings AG (OTC:RHHBY ... as measured by a composite disability over a period of at least 120 weeks of treatment. Also Read: Pharmaceutical Firms Say UK Investment Is ‘Unlikely’ Unless Payment ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.